In a statement, the AIM-listed speciality pharmaceutical group said Peter Butterfield, currently deputy CEO, will take over from John Dawson as CEO on 1 May 2018.
It added that Dawson, who founded Alliance in 1996, will remain on the board as a non-executive director.
Alliance Pharma also announced that following a search process involving internal and external candidates, as of today, David Cook - a non-executive director of the company for almost four years - will take over as its non-executive chairman from Andrew Smith, who will step down from Alliance's board.
Cook is a chartered accountant who worked in a professional practice for 13 years with PwC, following which he has worked for 14 years in the pharmaceutical industry, including having roles at EUSA Pharma Inc, Jazz Pharmaceuticals Ltd and Biotie Therapies Corporation. He is currently chief financial officer of Ellipses Pharma Limited.
Commenting on the Board changes, John Dawson said: "Peter Butterfield and I have worked closely together since he joined Alliance following our acquisition of Cambridge Laboratories eight years ago.
“His career path has been impressive and his capabilities give the Board the utmost confidence that, as CEO, Peter will be highly effective in driving the Company forward.”
The outgoing CEO added: "David Cook has been an invaluable Board member over the past four years and we are delighted that he has agreed to chair the Board as the Company continues on its growth trajectory.”
Butterfield, Alliance's Deputy CEO, commented: "I am delighted to be taking on the leadership of Alliance as it continues to grow. It has been a real pleasure working alongside John and I'm very pleased that he has decided to continue his involvement with the Company as a non-executive director."
In late afternoon trading, Alliance Pharma shares were off 0.7% at 67.2p.
-- Adds share price --